Lixte Biotechnology (LIXT) 10-K27 Mar 152014 FY Annual reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
Document and Entity Information (USD $)	Dec. 31, 2014	Mar. 20, 2015	Jun. 30, 2014
Document And Entity Information
Entity Registrant Name	LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Entity Central Index Key	1335105
Document Type	10-K
Document Period End Date	31-Dec-14
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Entity Well-Known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$1,898,350
Entity Common Stock, Shares Outstanding		45,575,814
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2014

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash	$44,411	$475,019
Money market funds	213,699	6,135
Advances on research and development contract services	231,177	33,880
Prepaid expenses and other current assets	50,012	43,006
Total current assets	539,299	558,040
Total assets	539,299	558,040
Current liabilities:
Accounts payable and accrued expenses	122,534	107,774
Research and development contract liabilities, including $18,436 and $34,398 to a related party at December 31, 2014 and 2013, respectively	58,186	47,283
Registration rights penalty obligation		74,000
Due to Chairman and major stockholder	92,717	92,717
Total current liabilities	273,437	321,774
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.0001 par value; authorized - 10,000,000 shares; issued - none
Common stock, $0.0001 par value; authorized - 100,000,000 shares; issued and outstanding - 45,483,097 shares and 41,583,097 shares at December 31, 2014 and 2013, respectively	4,548	4,158
Additional paid-in capital	15,979,475	13,184,081
Accumulated deficit	-15,718,161	-12,951,973
Total stockholders' equity	265,862	236,266
Total liabilities and stockholders' equity	$539,299	$558,040

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]
Research and development contract liabilities, related parties	$18,436	$34,398
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	45,483,097	41,583,097
Common stock, shares outstanding	45,483,097	41,583,097

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
Consolidated Statements of Operations (USD $)	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Revenues
Costs and expenses:
General and administrative costs, including $784,598 and $115,768 to related parties for the years ended December 31, 2014 and 2013, respectively	1,285,173	494,959
Research and development costs, including $435,707 and $304,102 to related parties for the years ended December 31, 2014 and 2013, respectively	1,117,970	879,886
Total costs and expenses	2,403,143	1,374,845
Loss from operations	-2,403,143	-1,374,845
Interest income	66	3
Fair value of warrant extensions	-302,691
Fair value of warrant discount	-134,420
Gain from reversal of registration rights penalty obligation	74,000
Net loss	($2,766,188)	($1,374,842)
Net loss per common share - Basic and diluted	($0.06)	($0.03)
Weighted average common shares outstanding - Basic and diluted	44,405,563	41,583,097

Consolidated_Statements_of_Ope1

Consolidated Statements of Operations (Parenthetical) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
General and administrative costs, to related parties	$784,598	$115,768
Research and development costs, to related parties	$435,707	$304,102

Consolidated_Statement_of_Stoc

Consolidated Statement of Stockholders' Equity (USD $)	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2012	$4,158	$13,064,831	($11,577,131)	$1,491,858
Balance, shares at Dec. 31, 2012	41,583,097
Stock-based compensation expense		119,250		119,250
Fair value of warrant extensions
Net loss			-1,374,842	-1,374,842
Balance at Dec. 31, 2013	4,158	13,184,081	-12,951,973	236,266
Balance, shares at Dec. 31, 2013	41,583,097
Stock-based compensation expense		946,173		946,173
Exercise of stock warrants	390	1,412,110		1,412,500
Exercise of stock warrants, shares	3,900,000
Fair value of warrant extensions		302,691		302,691
Fair value of warrant discount		134,420		134,420
Net loss			-2,766,188	-2,766,188
Balance at Dec. 31, 2014	$4,548	$15,979,475	($15,718,161)	$265,862
Balance, shares at Dec. 31, 2014	45,483,097

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
Consolidated Statements of Cash Flows (USD $)	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net loss	($2,766,188)	($1,374,842)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense included in - General and administrative costs	775,124	119,125
Stock-based compensation expense included in - Research and development costs	171,049	125
Fair value of warrant - Extensions	302,691
Fair value of warrant - Discount	134,420
(Increase) decrease in -
Advances on research and development contract services	-197,297	17,695
Prepaid expenses and other current assets	-7,006	-2,827
Increase (decrease) in -
Accounts payable and accrued expenses	14,760	27,358
Research and development contract liabilities	10,903	33,264
Registration rights penalty obligation	-74,000
Net cash used in operating activities	-1,635,544	-1,180,102
Cash flows from investing activities:
Increase in money market funds	-207,564	-1
Net cash used in investing activities	-207,564	-1
Cash flows from financing activities:
Proceeds from exercise of warrants	1,412,500
Net cash provided by financing activities	1,412,500
Cash:
Net decrease	-430,608	-1,180,103
Balance at beginning of period	475,019	1,655,122
Balance at end of period	44,411	475,019
Cash paid for -
Interest
Income taxes

Organization_and_Business_Oper

Organization and Business Operations	12 Months Ended
Organization and Business Operations	Dec. 31, 2014
Accounting Policies [Abstract]
Organization and Business Operations [Text Block]	1. Organization and Business Operations

	Organization and Business

	Lixte Biotechnology Holdings, Inc. (“Holdings”), a Delaware corporation, including its wholly-owned Delaware subsidiary, Lixte Biotechnology, Inc. (“Lixte”) (collectively, the “Company”), is engaged in research and development activities with respect to anti-cancer treatments and other common non-malignant diseases. The Company’s activities are subject to significant risks and uncertainties, including the need to obtain additional financing, as described below.

	The Company is considered a development stage company at December 31, 2014, as the Company has not yet commenced any revenue-generating operations, does not have any cash flows from operations, and is dependent on debt and equity funding to finance its operations. In June 2014, as discussed in Note 2, the Financial Accounting Standards Board issued new guidance that removed all incremental financial reporting requirements from generally accepted accounting principles in the United States for development stage entities. The Company early adopted this new guidance effective June 30, 2014, as a result of which all inception-to-date financial information and disclosures have been omitted at December 31, 2014.

	The Company’s common stock is traded on the OTCQB operated by the OTC Markets under the symbol “LIXT”.

	Operating Plans

	The Company’s primary focus is developing new treatments for human cancers for which better therapies are urgently needed. The scope of potential applications of the Company’s products has expanded to other common non-malignant diseases, including vascular diseases (heart attacks and stroke, diabetes, and genetic diseases, such as Gaucher’s disease) in which errors in normal cellular processing lead to loss of functions important to normal cell function. This has occurred because the targets selected by the Company have multiple functions in the cell, which when altered result in different disorders that may benefit by treatment from the Company’s products.

	The Company’s drug discovery process is based on discerning clues to potential new targets for disease treatments reported in the increasingly large body of literature identifying the molecular variants which characterize human cancers and other non-cancer disorders. The Company designs drugs for which there are existing data suggesting that they may affect the altered pathways of the cancer cell and may be given safely to humans. The Company seeks to rapidly arrive at patentable structures through analysis of the literature rather than screening of thousands of structures for activity against a particular biochemical pathway.

	This approach has led to the development of two classes of drugs for the treatment of cancer: protein phosphatase inhibitors (PTase-i), designated by the Company as the LB-100 series of compounds, and histone deacetylase inhibitors (HDACi), designated by the Company as the LB-200 series of compounds. Compounds of both types also have potential use in the prevention and treatment of neurodegenerative diseases. The LB-100 series consists of novel structures, which have the potential to be first in their class, and may be useful in the treatment of not only several types of cancer but also vascular and metabolic diseases. The LB-200 series contains compounds which have the potential to be the most effective in its class and may be useful for the treatment of chronic hereditary diseases, such as Gaucher’s disease, in addition to cancer and neurodegenerative diseases.

	On August 16, 2011, the United States Patent and Trademark Office (the “PTO”) awarded a patent to the Company for its lead compound, LB-100, as well as for a number of structurally related compounds. On November 15, 2011, the PTO awarded a patent to the Company for a lead compound in the LB-200 series and a compound in the LB-100 series as neuroprotective agents for the prevention and treatment of neurodegenerative diseases. On March 27, 2012, the PTO awarded a patent to the Company for its lead compound LB-201, as well as for a number of structurally related compounds. Patent applications on these compounds and their use are pending world-wide.

	The Company’s primary objective has been to bring one lead compound of the LB-100 series to clinical trial. In 2012, the Company completed the pre-clinical studies required to prepare an Investigational New Drug (“IND”) application to the United States Food and Drug Administration (“FDA”) to conduct a Phase 1 clinical trial of LB-100, and engaged Theradex Systems, Inc. (“Theradex”), an international contract research organization (“CRO”) that provides professional services for the clinical research and development of pharmaceutical compounds, to be responsible for the clinical development of the Company’s lead compound, LB-100, and to prepare an IND application for filing with the FDA.

	The Company filed an IND application with the FDA on April 30, 2012, and on July 24, 2012, the FDA notified the Company that it would allow initiation of a Phase 1 clinical trial of LB-100. The purpose of the clinical trial is to demonstrate that LB-100 can be administered safely to human beings at a dose and at a frequency that achieves the desired pharmacologic effect; in this case, inhibition of a specific enzyme, without being associated with toxicities considered unacceptable. The Phase 1 clinical trial of LB-100 is divided into two parts: the first part is designed to determine the maximum tolerable dose of LB-100 given alone, and the second part is designed to determine the maximum tolerable dose of LB-100 in combination with a standard widely used anti-cancer drug, docetaxel, a well-established anti-mitotic chemotherapy medication approved by the FDA for the treatment of various cancers.

	The Phase 1 clinical trial of LB-100 began in April 2013 with the entry of patients into the clinical trial (NCTO 1837667 at www.clinicaltrials.gov) and was initiated at the City of Hope National Medical Center in Duarte, California, and was extended in December 2013 to include the Mayo Clinic in Rochester, Minnesota, both of which are Comprehensive Cancer Centers designated by the National Cancer Institute. As the accrual of patients was slower than anticipated, in October 2014 the Company entered into a Clinical Research Agreement (“CRA”) with US Oncology Research, LLC, a large community-based research network based in Texas, to increase the rate of entry of patients into the ongoing clinical trial by adding four more active clinical oncologic research sites.

	The Company originally estimated that the Phase 1 clinical trial of LB-100 would be completed during the quarter ending June 30, 2015 at a total cost of approximately $2,038,000. The Company currently estimates that the first part of the clinical trial will be completed by June 30, 2015, and the second part of the clinical trial will be completed by June 30, 2016, at a total cost of approximately $2,615,000.

	The costs of the Phase 1 clinical trial of LB-100 are being paid to or through Theradex, the CRO responsible for the clinical development of LB-100. Total costs charged to operations through December 31, 2014 for services paid to or through Theradex pursuant to this arrangement, which were first incurred in 2013, totaled $702,255, of which $423,534 and $278,721 were incurred during the years ended December 31, 2014 and 2013, respectively. The final cost of the clinical trial is variable, depending upon the number of patients needed to be medically screened to determine if they meet the criteria for entry into the clinical trial and ultimately upon the total number of patients entered into the clinical trial to establish the proper doses of the drug for a Phase 2 clinical trial.

	The Phase 1 clinical trial of LB-100 is being conducted in two parts. In Part 1, the dose of LB-100 to be administered alone in a subsequent Phase 2 clinical trial is being determined, and in Part 2, the dose of LB-100, in combination with the standard cytotoxic drug docetaxel is being determined. Part 1 of the current clinical trial is anticipated to be concluded in the second quarter of 2015 and Part 2 of the current clinical trial is anticipated to be concluded in the second quarter of 2016.

	After completion of the Phase 1 clinical trial of LB-100, subject to the availability of funds, the Company anticipates that the next steps in its clinical development program will be to determine the anti-cancer activity of LB-100 as a single agent against a specific hematological cancer in a Phase 1/2 clinical trial, and in combination with docetaxel against a specific solid tumor in a Phase 2 clinical trial for which single agent docetaxel is indicated.

	Going Concern

	The Company’s consolidated financial statements have been presented on the basis that it is a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has not generated any revenues from operations to date, and does not expect to do so in the foreseeable future. The Company has experienced recurring operating losses and negative operating cash flows since inception, and has financed its working capital requirements during this period primarily through the recurring sale of its equity securities and the exercise of outstanding warrants. As a result, management believes that there is substantial doubt about the Company’s ability to continue as a going concern.

	The Company’s ability to continue as a going concern is dependent upon its ability to raise additional capital and to ultimately achieve sustainable revenues and profitable operations. The Company’s consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.

	At December 31, 2014, the Company had not yet commenced any revenue-generating operations. All activity through December 31, 2014 has been related to the Company’s capital raising efforts and research and development activities. As such, the Company has yet to generate any cash flows from operations, and is dependent on debt and equity funding from both related and unrelated parties to finance its operations.

	Because the Company is currently engaged in research at an early stage, it will likely take a significant amount of time to develop any product or intellectual property capable of generating revenues. As such, the Company’s business is unlikely to generate any sustainable revenues in the next several years, and may never do so. Even if the Company is able to generate revenues in the future through licensing its technologies or through product sales, there can be no assurance that the Company will be able to achieve positive earnings and cash flows from operations.

	At December 31, 2014, the Company had cash and money market funds aggregating $258,110. As a result of the Company receiving $1,750,000 from the sale of shares of preferred stock effective March 17, 2015 (see Note 9), the Company believes that it has sufficient funds to complete the ongoing Phase 1 clinical trial of its lead anti-cancer compound LB-100 and to fund its ongoing operating expenses, including maintaining its patent portfolio, through June 30, 2016.

	The amount and timing of future cash requirements will depend on the pace of the Company’s clinical programs, in particular the completion of the Phase 1 clinical trial of LB-100. The Company expects that it will need to raise additional capital no later than mid-2016, likely in the form of equity, to fund operations, including the continuing costs of its clinical trial program and to maintain its patent portfolio. However, academic investigators have recently published pre-clinical data suggesting that LB-100 alone and/or in combination with standard treatments may be useful in the treatment of two different hematologic cancers. As the single agent dose of LB-100 is expected to be determined by June 30, 2015, the Company may consider raising additional funds during 2015 for the conduct of a Phase 1b/II clinical trial of LB-100 in a hematologic malignancy before the Company completes Part 2 of the current Phase 1 clinical trial.

	Market conditions present uncertainty as to the Company’s ability to secure additional funds. There can be no assurances that the Company will be able to secure additional financing on acceptable terms, or at all, as and when necessary to continue to conduct operations. If cash resources are insufficient to satisfy the Company’s ongoing cash requirements, the Company would be required to scale back or discontinue its technology and product development programs and/or clinical trials, or obtain funds, if available (although there can be no certainty), through strategic alliances that may require the Company to relinquish rights to certain of its products, or to discontinue its operations entirely.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies

	Principles of Consolidation

	The accompanying consolidated financial statements of the Company are prepared in accordance with United States generally accepted accounting principles (“GAAP”) and include the financial statements of Holdings and its wholly-owned subsidiary, Lixte. Intercompany balances and transactions have been eliminated in consolidation.

	Cash Concentrations

	The Company’s cash balances may periodically exceed federally insured limits. The Company has not experienced a loss in such accounts to date. The Company maintains its accounts with financial institutions with high credit ratings.

	Research and Development

	Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s treatments and product candidates.

	Research and development costs are expensed as incurred over the life of the underlying contracts on the straight-line basis, unless the achievement of milestones, the completion of contracted work, or other information indicates that a different expensing schedule is more appropriate. Payments made pursuant to research and development contracts are initially recorded as advances on research and development contract services in the Company’s balance sheet and then charged to research and development costs in the Company’s statement of operations as those contract services are performed. Expenses incurred under research and development contracts in excess of amounts advanced are recorded as research and development contract liabilities in the Company’s balance sheet, with a corresponding charge to research and development costs in the Company’s statement of operations. The Company reviews the status of its research and development contracts on a quarterly basis.

	Patent Costs

	Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and any related patent applications, all patent costs, including patent-related legal and filing fees, are expensed as incurred. Patent costs were $342,625 and $405,582 for the years ended December 31, 2014 and 2013, respectively. Patent costs are included in research and development costs in the Company’s consolidated statements of operations.

	Concentration of Risk

	The Company periodically contracts with directors, including companies controlled by or associated with directors, to provide consulting services related to the Company’s research and development and clinical trial activities. Agreements for these services can be for a specific time period (typically one year) or for a specific project or task, and can include both cash and non-cash compensation. The only such contract that represents 10% or more of general and administrative or research and development costs is described below.

	On September 21, 2012, the Company entered into a work order agreement with Theradex, the CRO responsible for the clinical development of the Company’s lead compound, LB-100, to manage and administer the Phase 1 clinical trial of LB-100. Dr. Robert B. Royds, the founder, Chairman of the Board of Directors and Medical Director of Theradex, had been previously appointed to the Company’s Board of Directors on May 2, 2011 and died on March 23, 2013. The Phase 1 clinical trial of LB-100, which began during April 2013 with the entry of patients into the clinical trial, is being carried out by nationally recognized comprehensive cancer centers, and is estimated to be completed by June 30, 2016. The Phase 1 clinical trial is currently estimated to cost approximately $2,615,000, with such payments expected to be allocated approximately 60% for services provided by Theradex and approximately 40% for pass-through costs for clinical center laboratory costs and investigator costs. Total costs charged to operations through December 31, 2014 for services paid to or through Theradex pursuant to this arrangement, which were first incurred in 2013, totaled $702,255, of which $423,534 and $278,721 were incurred during the years ended December 31, 2014 and 2013, respectively, or approximately 38% and 32% of research and development costs for the years ended December 31, 2014 and 2013, respectively. The costs charged to operations for amounts paid to or through Theradex for services relating to the Phase 1 clinical trial of LB-100 are expected to represent a larger percentage of total research and development costs during the fiscal years ending December 31, 2015 and 2016 as compared to prior fiscal years. Costs pursuant to this agreement are included in research and development costs in the Company’s consolidated statements of operations (see Note 5).

	Income Taxes

	The Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities.

	The Company has elected to deduct research and development costs on a current basis for federal income tax purposes. For federal tax purposes, start-up and organization costs were deferred until January 1, 2008 at which time the Company began to amortize such costs over a 180-month period.

	The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made.

	The Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company’s net operating losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which the Company currently operates or has operated in the past. The Company had no unrecognized tax benefits as of December 31, 2014 and 2013 and does not anticipate any material amount of unrecognized tax benefits within the next 12 months.

	The Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The tax effects of a position are recognized only if it is “more-likely-than-not” to be sustained by the taxing authority as of the reporting date. If the tax position is not considered “more-likely-than-not” to be sustained, then no benefits of the position are recognized. As of December 31, 2014, the Company had not recorded any liability for uncertain tax positions. In subsequent periods, any interest and penalties related to uncertain tax positions will be recognized as a component of income tax expense.

	Stock-Based Compensation

	The Company periodically issues stock options to officers, directors and consultants for services rendered. Options vest and expire according to terms established at the grant date.

	The Company accounts for stock-based payments to officers and directors by measuring the cost of services received in exchange for equity awards based on the grant date fair value of the awards, with the cost recognized as compensation expense on the straight-line basis in the Company’s financial statements over the vesting period of the awards. The Company accounts for stock-based payments to consultants by determining the value of the stock compensation based upon the measurement date at either (a) the date at which a performance commitment is reached or (b) at the date at which the necessary performance to earn the equity instruments is complete.

	Options granted to members of the Company’s Scientific Advisory Committee and to outside consultants are revalued each reporting period to determine the amount to be recorded as an expense in the respective period. As the options vest, they are valued on each vesting date and an adjustment is recorded for the difference between the value already recorded and the then current value on the date of vesting.

	The fair value of stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is affected by several variables, the most significant of which are the life of the equity award, the exercise price of the security as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock over the term of the equity award.

	The Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development costs, as appropriate, in the Company’s statement of operations.

	The Company issues new shares to satisfy stock option exercises.

	Comprehensive Income (Loss)

	Components of comprehensive income or loss, including net income or loss, are reported in the financial statements in the period in which they are recognized. Comprehensive income or loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss) are reported net of any related tax effect to arrive at comprehensive income (loss). The Company did not have any items of comprehensive income (loss) for the years ended December 31, 2014 and 2013.

	Earnings Per Share

	The Company’s computation of earnings per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income (loss) available to common shareholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., warrants and options) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.

	Loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted loss per common share is the same for all periods presented because all warrants and stock options outstanding are anti-dilutive.

	At December 31, 2014 and 2013, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.

		December 31,
		2014		2013

Common stock warrants			2,928,800		6,828,800
Common stock options			6,850,000		3,150,000
Total			9,778,800		9,978,800

Fair Value of Financial Instruments

The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels, and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required.

Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives.

Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges.

Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models.

The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end.

Money market funds are the only financial instrument that is measured and recorded at fair value on the Company’s consolidated balance sheet on a recurring basis.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Recent Accounting Pronouncements

In May 2014, the FASB issued Accounting Standards Update No. 2014-09 (ASU 2014-09), Revenue from Contracts with Customers. ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. ASU 2014-09 also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for reporting periods beginning after December 15, 2016, and early adoption is not permitted. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. As the Company does not expect to have any operating revenues for the foreseeable future, the Company does not expect the adoption of this guidance to have any impact on the Company’s financial statement presentation or disclosures.

In June 2014, the FASB issued Accounting Standards Update No. 2014-10 (ASU 2014-10), Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. ASU 2014-10 eliminated the requirement to present inception-to-date information about income statement line items, cash flows, and equity transactions, and clarifies how entities should disclose the risks and uncertainties related to their activities. ASU 2014-10 also eliminated an exception provided to development stage entities in Consolidations (ASC Topic 810) for determining whether an entity is a variable interest entity on the basis of the amount of investment equity that is at risk. The presentation and disclosure requirements in Topic 915 will no longer be required for interim and annual reporting periods beginning after December 15, 2014, and the revised consolidation standards will take effect in annual periods beginning after December 15, 2015. Early adoption was permitted. The Company adopted the provisions of ASU 2014-10 effective June 30, 2014, and accordingly, is no longer presenting the inception-to-date financial information and disclosures formerly required in its financial statements.

In August 2014, the FASB issued Accounting Standards Update No. 2014-15 (ASU 2014-15), Presentation of Financial Statements – Going Concern (Subtopic 205-10). ASU 2014-15 provides guidance as to management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. In connection with preparing financial statements for each annual and interim reporting period, an entity’s management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). Management’s evaluation should be based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued (or at the date that the financial statements are available to be issued when applicable). Substantial doubt about an entity’s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued (or available to be issued). ASU 2014-15 is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company is currently evaluating the impact the adoption of ASU 2014-15 on the Company’s financial statement presentation and disclosures.

In January 2015, the FASB issued Accounting Standards Update No. 2015-01 (ASU 2015-01), Income Statement – Extraordinary and Unusual Items (Subtopic 225-20). ASU 2015-01 eliminates from GAAP the concept of extraordinary items. Subtopic 225-20, Income Statement—Extraordinary and Unusual Items, required that an entity separately classify, present, and disclose extraordinary events and transactions. Presently, an event or transaction is presumed to be an ordinary and usual activity of the reporting entity unless evidence clearly supports its classification as an extraordinary item. Paragraph 225-20-45-2 contains the following criteria that must both be met for extraordinary classification: (1) Unusual nature. The underlying event or transaction should possess a high degree of abnormality and be of a type clearly unrelated to, or only incidentally related to, the ordinary and typical activities of the entity, taking into account the environment in which the entity operates. (2) Infrequency of occurrence. The underlying event or transaction should be of a type that would not reasonably be expected to recur in the foreseeable future, taking into account the environment in which the entity operates. If an event or transaction meets the criteria for extraordinary classification, an entity is required to segregate the extraordinary item from the results of ordinary operations and show the item separately in the income statement, net of tax, after income from continuing operations. The entity also is required to disclose applicable income taxes and either present or disclose earnings-per-share data applicable to the extraordinary item. ASU 2015-01 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. A reporting entity may apply the guidance prospectively. A reporting entity also may apply the guidance retrospectively to all prior periods presented in the financial statements. Early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption. The adoption of ASU 2015-01 is not expected to have any impact on the Company’s financial statement presentation or disclosures.

In February 2015, the FASB issued Accounting Standards Update No. 2015-02 (ASU 2015-02), Consolidation (Topic 810). ASU 2015-02 changes the guidance with respect to the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. All legal entities are subject to reevaluation under the revised consolidation mode. ASU 2015-02 affects the following areas: (1) Limited partnerships and similar legal entities. (2) Evaluating fees paid to a decision maker or a service provider as a variable interest. (3) The effect of fee arrangements on the primary beneficiary determination. (4) The effect of related parties on the primary beneficiary determination. (5) Certain investment funds. ASU 2015-02 is effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. If an entity early adopts the guidance in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. A reporting entity may apply the amendments in this guidance using a modified retrospective approach by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption. A reporting entity also may apply the amendments retrospectively. The adoption of ASU 2015-02 is not expected to have any impact on the Company’s financial statement presentation or disclosures.

Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

Common_Stock_and_Common_Stock_

Common Stock and Common Stock Warrants	12 Months Ended
Common Stock and Common Stock Warrants	Dec. 31, 2014
Common Stock And Common Stock Warrants
Common Stock and Common Stock Warrants	3. Common Stock and Common Stock Warrants

	On January 28, 2014, the Company’s Board of Directors extended to June 30, 2014 outstanding warrants to acquire 1,748,800 shares of the Company’s common stock exercisable at $0.50 per share that were issued to investors and the placement agent in connection with private placements that closed on February 10, 2009, March 2, 2009 and April 6, 2009. On September 30, 2012, the Company had previously extended all other outstanding warrants to June 30, 2014. Included in the January 2014 extension were warrants to acquire 815,920 shares of common stock scheduled to expire on February 10, 2014, warrants to acquire 312,880 shares of common stock scheduled to expire on March 2, 2014, and warrants to acquire 620,000 shares of common stock scheduled to expire on April 6, 2014. The difference in the fair value of the warrants immediately before and after the grant of the extensions, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $78,617 (average of $0.04 per share), and such amount was charged to operations on January 28, 2014. The fair value of the warrant extensions was calculated using the following input variables: stock price - $0.15 per share; exercise price - $0.50 per share; expected life – 13 to 153 days; expected volatility – 262%; expected dividend yield - 0%; risk-free interest rate – 1.51%.

	On January 28, 2014, the Company offered to all of its warrant holders an inducement to exercise early by reducing the exercise price of currently outstanding warrants by 50%, if exercised on a cash basis by April 15, 2014. The exercise prices of the warrants before reduction were $0.50 per share (2,253,800 warrants) and $0.75 per share (4,575,000 warrants). The difference in the fair value of the warrants immediately before and after the grant of the discount, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $134,420 (an average of $0.02 per share), and such amount was charged to operations on January 28, 2014. The fair value of the warrant extensions was calculated using the following input variables: stock price - $0.15 per share; exercise price - $0.50 and $0.75 per share; expected life – 77 days (the period during which the discount was available); expected volatility – 262%; expected dividend yield - 0%; risk-free interest rate – 1.51%.

	As a result of the discount warrant offer, warrants to acquire 3,900,000 shares of the Company’s common stock were exercised in April 2014 at discounts ranging from $0.25 to $0.375 per share. The exercise of the warrants generated aggregate net proceeds to the Company of $1,412,500.

	On June 4, 2014, the Company’s Board of Directors extended to March 31, 2015 outstanding warrants to acquire 2,928,800 shares of the Company’s common stock that were issued to investors and the placement agent in connection with private placements that closed on February 10, 2009, March 2, 2009, April 6, 2009 and January 20, 2010, provided that the warrants were exercised in cash. Warrants to acquire 1,853,800 shares of the Company’s common stock were exercisable at $0.50 per share and 1,075,000 were exercisable at $0.75 per share. All warrants extended were scheduled to expire on June 30, 2014. The difference in the fair value of the warrants immediately before and after the grant of the extensions, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $224,074 (average of $0.08 per share), and such amount was charged to operations on June 4, 2014. The fair value of the warrant extensions was calculated using the following input variables: stock price - $0.22 per share; exercise price - $0.50 and $0.75 per share; expected life – 26 to 300 days; expected volatility – 173%; expected dividend yield - 0%; risk-free interest rate – 0.10%.

	A summary of common stock warrant activity, including warrants to purchase common stock that were issued in conjunction with the Company’s private placements, is presented below. For presentation purposes, warrants that were extended are considered as outstanding for the entire period in which such extension occurs.

											Weighted
											Average
							Weighted				Remaining
			Number				Average				Contractual
			of				Exercise				Life
			Shares				Price				(in Years)

	Warrants outstanding at December 31, 2012			6,828,800			$	0.667
	Issued			—				—
	Exercised			—				—
	Expired			—				—
	Warrants outstanding at December 31, 2013			6,828,000				0.667
	Issued			—				—
	Exercised			(3,900,000	)			0.263
	Expired			—				—
	Warrants outstanding at December 31, 2014			2,928,800			$	0.592				0.25

	Warrants exercisable at December 31, 2013			6,659,840			$	0.672
	Warrants exercisable at December 31, 2014			2,807,840			$	0.596				0.25

	The exercise prices of common stock warrants outstanding and exercisable are as follows at December 31, 2014:

					Warrants				Warrants
	Exercise				Outstanding				Exercisable
	Prices				(Shares)				(Shares)

	$	0.5				1,853,800				1,732,840
	$	0.75				1,075,000				1,075,000
						2,928,800				2,807,840

	Based on a fair market value of $0.24 per share on December 31, 2014, there were no exercisable but unexercised in-the-money common stock warrants on that date. Accordingly, there was no intrinsic value attributed to exercisable but unexercised common stock warrants at December 31, 2014.

	Based on a fair market value of $0.13 per share on December 31, 2013, there were no exercisable but unexercised in-the-money common stock warrants on that date. Accordingly, there was no intrinsic value attributed to exercisable but unexercised common stock warrants at December 31, 2013

	At December 31, 2014, warrants exercisable do not include warrants to acquire 120,960 shares of common stock that are contingent upon the exercise of warrants contained in units sold as part of the third private placement.

	Registration Rights Penalty Obligation

	In conjunction with the Company’s private placement of its securities completed on July 27, 2006, the Company entered into a registration rights agreement with the purchasers, whereby the Company agreed to register the shares of common stock sold in the private placement, and to maintain the effectiveness of such registration statement, subject to certain conditions. The agreement required the Company to file a registration statement within 45 days of the closing of the private placement and to have the registration statement declared effective within 120 days of the closing of the private placement. Since the registration statement was not declared effective by the Securities and Exchange Commission within 120 days of the closing of the private placement, the Company was required to pay each investor prorated liquidated damages equal to 1.0% of the amount raised per month, payable monthly in cash. On September 8, 2006, the Company filed a registration statement on Form SB-2 to register 3,555,220 shares of the common stock sold in the private placement, and the registration statement was declared effective by the Securities and Exchange Commission on May 14, 2007.

	In accordance with EITF 00-19-2, “Accounting for Registration Payment Arrangements”, at December 31, 2006, the Company determined that the registration statement covering the shares sold in the private placement would not be declared effective within the requisite time frame. As a result, the Company recorded a registration rights penalty obligation under the registration rights agreement aggregating $74,000 at such date. The Company did not make any payments to the investors with respect to the registration rights penalty obligation through December 31, 2014, and it has determined that it is extremely remote that the Company will ever make such payments to the investors. Accordingly, at December 31, 2014, the Company recorded a gain of $74,000 from the reversal of the registration rights penalty obligation in the Company’s consolidated statement of operations.

Money_Market_Funds

Money Market Funds	12 Months Ended
Money Market Funds	Dec. 31, 2014
Investments, Debt and Equity Securities [Abstract]
Money Market Funds	4. Money Market Funds

	Money market funds at December 31, 2014 and 2013 consisted of investments in shares of Morgan Stanley New York Municipal Money Market Trust with a market value of $213,699 and $6,135, respectively.

	The Morgan Stanley New York Municipal Money Market Trust is an open-end fund incorporated in the USA. The Fund’s objective is as high level of daily income exempt from federal and New York income tax as is consistent with stability of principal and liquidity. The Fund invests in high quality, short- term municipal obligations that pay interest exempt from federal and NY taxes.

	The following table presents money market funds at their level within the fair value hierarchy at December 31, 2014 and 2013.

		Total		Level 1		Level 2		Level 3

	December 31, 2014:
	Money market funds	$	213,699	$	213,699	$	—	$	—

	December 31, 2013:
	Money market funds	$	6,135	$	6,135	$	—	$	—

Related_Party_Transactions

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2014
Related Party Transactions [Abstract]
Related Party Transactions	5. Related Party Transactions

	Advances from the Company’s Chairman and major stockholder, Dr. John Kovach, aggregating $92,717 at December 31, 2014 and 2013 are non-interest bearing and are due on demand, and were included in current liabilities in the Company’s consolidated balance sheets. Subsequent to December 31, 2014, such advances were converted into shares of common stock (see Note 9).

	Dr. Kovach was paid a salary of $60,000 for the years ended December 31, 2014 and 2013, which amounts are included in general and administrative costs in the Company’s consolidated statements of operations.

	Dr. Kovach is not involved in other business activities but could, in the future, become involved in other business opportunities that become available. Accordingly, Dr. Kovach may face a conflict in selecting between the Company and his other business interests. The Company has not yet formulated a policy for the resolution of such potential conflicts.

	The Company’s principal office facilities have been provided without charge by Dr. Kovach. Such costs were not material to the consolidated financial statements and, accordingly, have not been reflected therein.

	On June 18, 2014, the Company entered into a sub-lease agreement for shared office space in New York City with the Eric Forman Law Office, a party providing legal and consulting services to the Company. The sub-lease was for a term of six months at a base rate of $875 per month and was not renewed upon expiration. Eric Forman is the son-in-law of Gil Schwartzberg, a significant stockholder of and consultant to the Company. Legal and consulting fees charged to operations for services rendered by Eric Forman for the years ended December 31, 2014 and 2013 were $46,000 and $12,000, respectively.

	On May 21, 2012, the Company entered into an agreement with Dr. Mel Sorensen, a former member of the Company’s Board of Directors, for consultation and advice regarding the preparation and strategy for obtaining FDA allowance of a clinical trial of the lead compound of the LB-100 series. The term of the agreement was for the period from May 21, 2012 to May 31, 2013 and provided for a fee of $25,000, payable in two installments of $12,500 on May 21, 2012 and December 1, 2012. Consulting and advisory fees charged to operations pursuant to this agreement were $10,417 for the year ended December 31, 2013 and are included in research and development costs in the Company’s consolidated statements of operations. Effective April 16, 2014, Dr. Sorenson resigned from the Company’s Board of Directors for personal reasons.

	Periodically, the Company has entered into agreements with Ascentage Pharma Group to conduct various studies. Ascentage Pharma Group is a spin-off of Ascenta Therapeutics, of which Dr. Sorensen is the President and Chief Executive Officer and a director. Ascentage Pharma Group and Ascenta Therapeutics have a continuing business relationship and certain common shareholders. However, Dr. Sorensen does not have any direct business relationship with or ownership in Ascentage Pharma Group.

	On September 21, 2012, the Company entered into a work order agreement with Theradex, the CRO responsible for the clinical development of the Company’s lead compound, LB-100, to manage and administer the Phase 1 clinical trial of LB-100. Dr. Robert B. Royds, the founder, Chairman of the Board of Directors and Medical Director of Theradex, had been previously appointed to the Company’s Board of Directors on May 2, 2011 and died on March 23, 2013. The Phase 1 clinical trial of LB-100, which began during April 2013 with the entry of patients into the clinical trial, is being carried out by nationally recognized comprehensive cancer centers, and is estimated to be completed by June 30, 2016. The Phase 1 clinical trial is currently estimated to cost approximately $2,615,000, with such payments expected to be allocated approximately 60% for services provided by Theradex and approximately 40% for pass-through costs for clinical center laboratory costs and investigator costs. Total costs charged to operations through December 31, 2014 for services paid to or through Theradex pursuant to this arrangement, which were first incurred in 2013, totaled $702,255, of which $423,534 and $278,721 were incurred during the years ended December 31, 2014 and 2013, respectively. Costs pursuant to this agreement are included in research and development costs in the Company’s consolidated statements of operations.

	In addition to the above described agreement with Theradex, the Company has also from time to time engaged Theradex to assist the Company in bringing LB-100 through the FDA approval process and to provide other regulatory services. These costs were not material for all periods presented.

	Effective January 1, 2014, the Company entered into an Advisory Agreement with Dr. Kathleen P. Mullinix, a member of the Board of Directors of the Company, effective for an initial term of one year through December 31, 2014 to advise on business development matters. The Advisory Agreement provides for annual cash compensation of $25,000. The term of the Advisory Agreement is automatically extended for a term of one year annually unless a notice of intent to terminate is given by either party at least 90 days before the end of the applicable term. Accordingly, the Advisory Agreement was extended for an additional term of one year effective January 1, 2015. The Company charged $25,000 to operations for services provided under this agreement during the year ended December 31, 2014, which amount was included in general and administrative costs in the Company’s consolidated statements of operations.

	Stock-based compensation arrangements involving members of the Company’s Board of Directors are described at Note 6. Total stock-based compensation expense relating to directors, officers and other related parties was $946,173 and $119,250 for the years ended December 31, 2014 and 2013, respectively.

StockBased_Compensation

Stock-Based Compensation	12 Months Ended
Stock-Based Compensation	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	6. Stock-Based Compensation

	The Company grants stock options as incentive compensation to directors and as compensation for the services of independent contractors and consultants of the Company.

	On June 20, 2007, the Board of Directors of the Company approved the 2007 Stock Compensation Plan (the “2007 Plan”), which provides for the granting of awards, consisting of common stock options, stock appreciation rights, performance shares, or restricted shares of common stock, to employees and independent contractors, for up to 2,500,000 shares of the Company’s common stock, under terms and condition, as determined by the Company’s Board of Directors. As of December 31, 2014, stock options for 650,000 shares had been issued under the 2007 Plan, and stock options for 1,850,000 were available for issuance under the 2007 Plan.

	The fair value of each option awarded is estimated on the date of grant and subsequent measurement dates using the Black-Scholes option-pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options. In addition, option valuation models require the input of highly subjective assumptions including the expected stock price volatility. Because the Company’s stock options have characteristics significantly different from those of traded options, and because changes in the subjective assumptions can materially affect the fair value estimate, in management’s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its stock options. The expected dividend yield assumption is based on the Company’s expectation of dividend payouts. Expected volatilities are based on historical volatility of the Company’s stock. The risk-free interest rate is based on the U.S. treasury yield curve in effect as of the grant date. Expected life of the options is the average of the vesting term and the full contractual term of the options.

	For options granted during the year ended December 31, 2014, the fair value of each option award was estimated using the Black-Scholes option-pricing model with the following assumptions:

	Risk-free interest rate		1.15% to 1.75	%
	Expected dividend yield		0	%
	Expected volatility		173% to 380	%
	Expected life		4-5 years

	For options granted during the year ended December 31, 2013, the fair value of each option award was estimated using the Black-Scholes option-pricing model with the following assumptions:

	Risk-free interest rate		1.51	%
	Expected dividend yield		0	%
	Expected volatility		262	%
	Expected life		5 years

	On June 30, 2011, the Company granted to Dr. Philip F. Palmedo, a director of the Company, stock options to purchase 200,000 shares of common stock, exercisable for a period of five years from the date of grant at $0.98 per share, which was the fair market value of the Company’s common stock on such date. The options vest ratably in equal quarterly installments of 25,000 shares beginning July 1, 2011. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was initially determined to be $196,000 ($0.98 per share). During the years ended December 31, 2014 and 2013, the Company recorded charges to operations of $-0- and $48,530, respectively, with respect to these options.

	On June 30, 2011, the Company granted to Dr. Iwao Ojima, a member of the Company’s Scientific Advisory Committee, stock options to purchase 50,000 shares of common stock, exercisable for a period of five years from the date of grant at $0.98 per share, which was the fair market value of the Company’s common stock on such date. The options vest ratably in equal quarterly installments of 6,250 shares beginning July 1, 2011. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was initially determined to be $49,000 ($0.98 per share). During the years ended December 31, 2014 and 2013, the Company charged operations of $-0- and $3,357, respectively, with respect to these options.

	On January 28, 2014, the Company approved a second amendment to the Company’s consulting agreement with Gil Schwartzberg, a significant stockholder of and consultant to the Company, dated September 12, 2007 to extend it for an additional four years to January 28, 2019 and granted to Mr. Schwartzberg stock options to purchase an additional aggregate of 4,000,000 shares of common stock, exercisable for a period of the earlier of five years from the grant date or the termination of the consulting agreement at $0.50 per share, with one-half of the options (2,000,000 shares) vesting immediately and one-half of the options (2,000,000 shares) vesting on January 28, 2015. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $596,400 ($0.15 per share) on January 28, 2014, of which $298,200 was attributed to the options fully-vested on January 28, 2014 and as such was charged to operations on that date. The remaining unvested portion of the fair value of the options is being charged to operations ratably from January 28, 2014 through January 28, 2015. During the year ended December 31, 2014, the Company recorded a charge to operations of $434,499 with respect to the remaining unvested portion of the options.

	Effective May 1, 2011, in connection with his election to the Company’s Board of Directors, Dr. Robert B. Royds was granted stock options to purchase 200,000 shares of the Company’s common stock, vesting 25,000 shares on May 1, 2011, and 25,000 shares quarterly thereafter until all of the shares are vested, exercisable for a period of five years from each tranche’s vesting date, at $0.98 per share, which was the fair market value of the Company’s common stock on such date. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $196,000 ($0.98 per share), and was charged to operations ratably from May 2, 2011 through February 1, 2013. During the year ended December 31, 2013, the Company recorded a charge to operations of $8,548 with respect to these options. Dr. Royds died on March 23, 2013 and the stock options expired unexercised on March 23, 2014.

	Effective September 16, 2012, in connection with her election to the Company’s Board of Directors, Dr. Kathleen P. Mullinix was granted stock options to purchase 200,000 shares of the Company’s common stock, vesting 25,000 shares on September 16, 2012, and 25,000 shares quarterly thereafter until all of the shares are vested, exercisable for a period of five years from the date of grant at $0.65 per share, which was the fair market value of the Company’s common stock on such date. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $118,000 ($0.59 per share), and was being charged to operations from September 16, 2012 through June 16, 2014. During the years ended December 31, 2014 and 2013, the Company recorded charges to operations of $26,899 and $58,690, respectively, with respect to these options.

	On December 24, 2013, the Company entered into an agreement with NDA Consulting Corp. (“NDA”) for consultation and advice in the field of oncology research and drug development. As part of the agreement, NDA agreed to cause its president, Dr. Daniel D. Von Hoff, M.D., to become a member of the Company’s Scientific Advisory Committee. In connection with this agreement, NDA was granted stock options to purchase 100,000 shares of the Company’s common stock, vesting 25,000 shares on June 24, 2014, and thereafter 25,000 shares annually on June 24, 2015, 2016 and 2017, exercisable for a period of five years from the date of grant at $0.13 per share, which was the fair market value of the Company’s common stock on the grant date. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was initially determined to be $12,960 ($0.13 per share), and is being charged to operations from December 24, 2013 through June 24, 2017. During the year ended December 31, 2014, the Company recorded a charge to operations of $8,901 with respect to these options.

	On June 26, 2014, the Company granted to Francis Johnson, a consultant to the Company and a co-owner of Chem-Master International, Inc., a vendor of the Company, immediately vesting stock options to purchase 500,000 shares of common stock, exercisable for a period of five years from the grant date at $0.25 per share. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $118,650 ($0.24 per share), which was charged to operations on that date. The options were granted to Mr. Johnson as compensation for his contributions to the Company’s compound development activities.

	On July 15, 2014, Gil Schwartzberg assigned fully-vested stock options to acquire 1,000,000 shares of the Company’s common stock to Daniel Von Hoff, a member of the Company’s Scientific Advisory Committee. The options assigned included options to acquire 500,000 shares that had been previously granted to Mr. Schwartzberg on October 15, 2009, were exercisable at $1.00 per share, and expired on October 15, 2014, and options for 500,000 shares that had been previously granted to Mr. Schwartzberg on October 5, 2011, are exercisable at $1.00 per share, and expire on October 5, 2016. As Mr. Schwartzberg is considered an affiliate of the Company for accounting and securities purposes, the fair value of the stock options assigned by Mr. Schwartzberg to Mr. Von Hoff for the benefit of the Company was recorded as a contribution to capital and a charge to operations. The fair value of the stock options assigned, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $43,500 (average of $0.04 per share), and such amount was charged to operations on July 15, 2014. The remaining unexpired stock options to acquire 500,000 shares were transferred back to Mr. Schwartzberg on February 23, 2015.

	On October 7, 2014, the Company entered into an Advisory Agreement with Andrew Robell for consultation and advice with respect to identifying and assessing potential licensing and strategic opportunities through September 30, 2016. In connection with the agreement, the Company’s Board of Directors granted stock options to Mr. Robell to purchase 200,000 shares of the Company’s common stock, vesting 100,000 shares on October 7, 2014 and 100,000 shares on October 7, 2015, exercisable for a period of five years from the date of grant at $0.50 per share. The fair value of these options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $20,000 ($0.10 per share), of which $10,000 is attributed to the options fully-vested on October 7, 2014 and as such was charged to operations on that date. The remaining unvested portion of the fair value of the options will be charged to operations ratably from October 7, 2014 through October 7, 2015. During the year ended December 31, 2014, the Company recorded a charge to operations of $15,526 with respect to these options.

	A summary of stock option activity is presented in the tables below.

								Weighted
								Average
					Weighted			Remaining
		Number			Average			Contractual
		Of			Exercise			Life
		Shares			Price			(in Years)

	Options outstanding at December 31, 2012		3,750,000		$	0.87
	Granted		100,000			0.13
	Exercised		—			—
	Expired		(700,000	)		1.045
	Options outstanding at December 31, 2013		3,150,000			0.818
	Granted		4,700,000			0.473
	Exercised		—			—
	Expired		(1,000,000	)		0.803
	Options outstanding at December 31, 2014		6,850,000		$	0.582			3.57

	Options exercisable at December 31, 2013		3,000,000		$	0.843
	Options exercisable at December 31, 2014		4,675,000		$	0.626			2.84

	Total deferred compensation expense for the outstanding value of unvested stock options was approximately $69,000 at December 31, 2014, which is being recognized subsequent to December 31, 2014 over a weighted-average period of approximately nine months.

The exercise prices of common stock options outstanding and exercisable are as follows at December 31, 2014:

			Options			Options
Exercise			Outstanding			Exercisable
Prices			(Shares)			(Shares)

$	0.13			100,000			25,000
$	0.25			500,000			500,000
$	0.5			4,300,000			2,200,000
$	0.65			700,000			700,000
$	0.98			250,000			250,000
$	1			1,000,000			1,000,000
				6,850,000			4,675,000

The intrinsic value of exercisable but unexercised in-the-money stock options at December 31, 2014 was approximately $2,750, based on a fair market value of $0.24 per share on December 31, 2014.

Based on a fair market value of $0.13 per share on December 31, 2013, there were no exercisable but unexercised in-the-money stock options on that date. Accordingly, there was no intrinsic value attributed to exercisable but unexercised stock options at December 31, 2013.

Outstanding options to acquire 2,175,000 shares of the Company’s common stock had not vested at December 31, 2014.

The Company expects to satisfy such stock obligations through the issuance of authorized but unissued shares of common stock.

Income_Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	7. Income Taxes

	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets as of December 31, 2014 and 2013 are summarized below.

		December 31,
		2014			2013
	Start-up and organization costs	$	49,000		$	56,000
	Research credits		139,000			95,000
	Contingent liability		31,000			31,000
	Stock-based compensation		952,000			750,000
	Net operating loss carryforwards		3,532,000			2,939,000
	Total deferred tax assets		4,703,000			3,871,000
	Valuation allowance		(4,703,000	)		(3,871,000	)
	Net deferred tax assets	$	—		$	—

	In assessing the potential realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the Company attaining future taxable income during the periods in which those temporary differences become deductible. As of December 31, 2014 and 2013, management was unable to determine if it is more likely than not that the Company’s deferred tax assets will be realized, and has therefore recorded an appropriate valuation allowance against deferred tax assets at such dates.

	No federal tax provision has been provided for the years ended December 31, 2014 and 2013 due to the losses incurred during such periods. Reconciled below is the difference between the income tax rate computed by applying the U.S. federal statutory rate and the effective tax rate for the years ended December 31, 2014 and 2013.

		Years Ended
		December 31,
		2014			2013

	U. S. federal statutory tax rate		(34.0	)%		(34.0	)%
	Non-deductible stock-based compensation		0.5	%		—	%
	Non-deductible fair value of warrant extensions		3.6	%		—	%
	Non-deductible fair value of warrant discounts		1.6	%		—	%
	Expirations related to stock-based compensation		5	%		13.8	%
	Adjustment to deferred tax asset		(1.0	)%		(1.3	)%
	Change in valuation allowance		24.3	%		21.5	%
	Effective tax rate		0	%		0	%

	At December 31, 2014, the Company has available net operating loss carryforwards for federal income tax purposes of approximately $8,507,000 which, if not utilized earlier, expire through 2033.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies

	On September 21, 2012, the Company entered into a work order agreement with Theradex, the CRO responsible for the clinical development of the Company’s lead compound, LB-100, to manage and administer the Phase 1 clinical trial of LB-100. The Phase 1 clinical trial of LB-100, which began during April 2013 with the entry of patients into the clinical trial, is being carried out by nationally recognized comprehensive cancer centers, and is estimated to be completed by June 30, 2015. The Phase 1 clinical trial is currently estimated to cost approximately $2,615,000, with such payments expected to be allocated approximately 60% for services provided by Theradex and approximately 40% for pass-through costs for clinical center laboratory costs and investigator costs. Total costs charged to operations through December 31, 2014 for services paid to or through Theradex pursuant to this arrangement, which were first incurred in 2013, totaled $702,255, of which $423,534 and $278,721 were incurred during the years ended December 31, 2014 and 2013, respectively. Costs pursuant to this agreement are included in research and development costs in the Company’s consolidated statements of operations.

	On December 24, 2013, the Company entered into an agreement with NDA Consulting Corp. (“NDA”) for consultation and advice in the field of oncology research and drug development. As part of the agreement, NDA agreed to cause its president, Dr. Daniel D. Von Hoff, M.D., to become a member of the Company’s Scientific Advisory Committee. The term of the agreement is for one year and provides for a quarterly cash fee of $4,000. The agreement was automatically renewed on its anniversary date for an additional one year term. Consulting and advisory fees charged to operations pursuant to this agreement were $16,000 during the year ended December 31, 2014.

	Effective January 1, 2014, the Company entered into an Advisory Agreement with Dr. Kathleen P. Mullinix, a member of the Board of Directors of the Company, effective for an initial term of one year through December 31, 2014 to advise on business development matters. The Advisory Agreement provides for annual cash compensation of $25,000. The term of the Advisory Agreement is automatically extended for a term of one year annually unless a notice of intent to terminate is given by either party at least 90 days before the end of the applicable term. Accordingly, the Advisory Agreement was extended for an additional term of one year effective January 1, 2015. The Company charged $25,000 to operations for services provided under this agreement during the year ended December 31, 2014, which amount was included in general and administrative costs in the Company’s consolidated statements of operations.

	The following table sets forth the Company’s principal cash obligations and commitments for the next five fiscal years as of December 31, 2014 aggregating $1,839,548, of which $150,903 is included in current liabilities in the Company’s consolidated balance sheet at December 31, 2014.

				Payments Due By Year
		Total		2015		2016		2017		2018		2019

	Research and development contracts	$	60,530	$	60,530	$	—	$	—	$	—	$	—
	Clinical trial agreements		1,670,301		1,020,301		650,000		—		—		—
	Consulting agreements		16,000		16,000		—		—		—		—
	Due to Chairman and major stockholder		92,717		92,717		—		—		—		—
	Total	$	1,839,548	$	1,189,548	$	650,000	$	—	$	—	$	—

Subsequent_Events

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	9. Subsequent Events

	On March 6, 2015, the Company advised holders of its outstanding common stock purchase warrants that it would extend the expiration date of the warrants, all of which are currently scheduled to expire on March 31, 2015, to April 15, 2015, and that it would reduce the cash exercise prices of the warrants by 50%. Warrants are currently outstanding to acquire a total of 2,928,800 shares of common stock, of which 1,075,000 warrants are exercisable at $0.75 per share and 1,853,800 warrants are exercisable at $0.50 per share. If all of the outstanding warrants are exercised, the Company would receive cash proceeds of $866,575 and the Company would issue 2,928,800 shares of common stock, reflecting an average exercise price of approximately $0.30 per share. The Company expects to record a charge to operations of approximately $200,000 during the three months ending March 31, 2015 with respect to the extension of the warrants and the reduction in the warrant exercise price.

	Effective March 17, 2015, the Company’s Chairman and major stockholder converted advances due to him aggregating $92,717 into 92,717 shares of the Company’s common stock, reflecting an effective price of $1.00 per share. On the effective date of the transaction, the closing price of the Company’s common stock was $0.25 per share.

	Effective March 17, 2015, the Company entered into a Securities Purchase Agreement with a current stockholder of the Company who owned 10.6% of the Company’s issued and outstanding shares of common stock immediately prior to the financing transaction, pursuant to which such stockholder purchased 175,000 shares of the Company’s non-voting Series A Convertible Preferred Stock (the “Preferred Shares”) at a price per share of $10.00, representing an aggregate purchase price of $1,750,000. The Preferred Shares have a dividend of 1% of the annual net revenue of the Company until converted or redeemed. Each of the Preferred Shares may be converted, at the option of the holder, into 12.5 shares of common stock (subject to customary anti-dilution provisions) and the Preferred Shares are subject to mandatory conversion at the conversion rate in the event of a merger or sale transaction resulting in gross proceeds to the Company of at least $21,875,000. If fully converted, the Preferred Shares would convert into 2,187,500 shares of common stock, representing an effective price per share of common stock of $0.80. On the effective date of the transaction, the closing price of the Company’s common stock was $0.25 per share. The Company has the right to redeem the Preferred Shares up to the fifth anniversary of the closing date at a price per share equal to $50.00. The Company will account for the Preferred Shares as a component of shareholders’ equity.

	The following table sets forth the condensed consolidated balance sheet of the Company as of December 31, 2014 on an as reported basis and on an unaudited pro forma basis, giving effect to the sale on March 17, 2015, of 175,000 shares of the Company’s Series A Convertible Preferred Stock at a price of $10.00 per share, representing an aggregate purchase price of $1,750,000, and the conversion of $92,717 of advances to the Company by Dr. John Kovach, the Company’s Chief Executive Officer, into 92,717 shares of the Company’s common stock, also on March 17, 2015.

		Actual - As			Pro Forma - As
		Reported			Adjusted
					(Unaudited)
	ASSETS
	Total current assets	$	539,299		$	2,289,299
	Total assets	$	539,299		$	2,289,299

	LIABILITIES AND STOCKHOLDERS’ EQUITY
	Total current liabilities	$	273,437		$	180,720
	Total liabilities		273,437			180,720

	STOCKHOLDERS’ EQUITY
	Series A convertible preferred stock, $0.0001 par value, $10.00 per share stated value, $50.00 per share redemption value; aggregate dividend equal to 1% of annual net revenue; aggregate redemption value of $8,750,000; liquidation preference based on conversion to common shares; preferred shares authorized: 175,000; preferred shares issued and outstanding: 175,000; common shares issuable upon conversion at 12.5 common shares per share of preferred stock: 2,187,500 shares, as adjusted		—			1,750,000
	Common stock, $0.0001 par value, authorized – 100,000,000 shares; issued and outstanding – 45,483,097 shares, as reported, and 45,575,814 shares, as adjusted		4,548			4,557
	Additional paid-in capital		15,979,475			16,072,183
	Accumulated deficit		(15,718,161	)		(15,718,161	)
	Total stockholders’ equity		265,862			2,108,579
	Total liabilities and stockholders’ equity	$	539,299		$	2,289,299

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation

	The accompanying consolidated financial statements of the Company include the financial statements of Holdings and its wholly-owned subsidiary, Lixte. Intercompany balances and transactions have been eliminated in consolidation.
Cash Concentrations	Cash Concentrations

	The Company’s cash balances may periodically exceed federally insured limits. The Company has not experienced a loss in such accounts to date. The Company maintains its accounts with financial institutions with high credit ratings.
Research and Development	Research and Development

	Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s treatments and product candidates.

	Research and development costs are expensed as incurred over the life of the underlying contracts on the straight-line basis, unless the achievement of milestones, the completion of contracted work, or other information indicates that a different expensing schedule is more appropriate. Payments made pursuant to research and development contracts are initially recorded as advances on research and development contract services in the Company’s balance sheet and then charged to research and development costs in the Company’s statement of operations as those contract services are performed. Expenses incurred under research and development contracts in excess of amounts advanced are recorded as research and development contract liabilities in the Company’s balance sheet, with a corresponding charge to research and development costs in the Company’s statement of operations. The Company reviews the status of its research and development contracts on a quarterly basis.
Patent Costs	Patent Costs

	Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and any related patent applications, all patent costs, including patent-related legal and filing fees, are expensed as incurred. Patent costs were $342,625 and $405,582 for the years ended December 31, 2014 and 2013, respectively. Patent costs are included in research and development costs in the Company’s consolidated statements of operations.
Concentration of Risk	Concentration of Risk

	The Company periodically contracts with directors, including companies controlled by or associated with directors, to provide consulting services related to the Company’s research and development and clinical trial activities. Agreements for these services can be for a specific time period (typically one year) or for a specific project or task, and can include both cash and non-cash compensation. The only such contract that represents 10% or more of general and administrative or research and development costs is described below.

	On September 21, 2012, the Company entered into a work order agreement with Theradex, the CRO responsible for the clinical development of the Company’s lead compound, LB-100, to manage and administer the Phase 1 clinical trial of LB-100. Dr. Robert B. Royds, the founder, Chairman of the Board of Directors and Medical Director of Theradex, had been previously appointed to the Company’s Board of Directors on May 2, 2011 and died on March 23, 2013. The Phase 1 clinical trial of LB-100, which began during April 2013 with the entry of patients into the clinical trial, is being carried out by nationally recognized comprehensive cancer centers, and is estimated to be completed by June 30, 2016. The Phase 1 clinical trial is currently estimated to cost approximately $2,615,000, with such payments expected to be allocated approximately 60% for services provided by Theradex and approximately 40% for pass-through costs for clinical center laboratory costs and investigator costs. Total costs charged to operations through December 31, 2014 for services paid to or through Theradex pursuant to this arrangement, which were first incurred in 2013, totaled $702,255, of which $423,534 and $278,721 were incurred during the years ended December 31, 2014 and 2013, respectively, or approximately 38% and 32% of research and development costs for the years ended December 31, 2014 and 2013, respectively. The costs charged to operations for amounts paid to or through Theradex for services relating to the Phase 1 clinical trial of LB-100 are expected to represent a larger percentage of total research and development costs during the fiscal years ending December 31, 2015 and 2016 as compared to prior fiscal years. Costs pursuant to this agreement are included in research and development costs in the Company’s consolidated statements of operations (see Note 5).
Income Taxes	Income Taxes

	The Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities.

	The Company has elected to deduct research and development costs on a current basis for federal income tax purposes. For federal tax purposes, start-up and organization costs were deferred until January 1, 2008 at which time the Company began to amortize such costs over a 180-month period.

	The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made.

	The Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company’s net operating losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which the Company currently operates or has operated in the past. The Company had no unrecognized tax benefits as of December 31, 2014 and 2013 and does not anticipate any material amount of unrecognized tax benefits within the next 12 months.

	The Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The tax effects of a position are recognized only if it is “more-likely-than-not” to be sustained by the taxing authority as of the reporting date. If the tax position is not considered “more-likely-than-not” to be sustained, then no benefits of the position are recognized. As of December 31, 2014, the Company had not recorded any liability for uncertain tax positions. In subsequent periods, any interest and penalties related to uncertain tax positions will be recognized as a component of income tax expense.
Stock-Based Compensation	Stock-Based Compensation

	The Company periodically issues stock options to officers, directors and consultants for services rendered. Options vest and expire according to terms established at the grant date.

	The Company accounts for stock-based payments to officers and directors by measuring the cost of services received in exchange for equity awards based on the grant date fair value of the awards, with the cost recognized as compensation expense on the straight-line basis in the Company’s financial statements over the vesting period of the awards. The Company accounts for stock-based payments to consultants by determining the value of the stock compensation based upon the measurement date at either (a) the date at which a performance commitment is reached or (b) at the date at which the necessary performance to earn the equity instruments is complete.

	Options granted to members of the Company’s Scientific Advisory Committee and to outside consultants are revalued each reporting period to determine the amount to be recorded as an expense in the respective period. As the options vest, they are valued on each vesting date and an adjustment is recorded for the difference between the value already recorded and the then current value on the date of vesting.

	The fair value of stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is affected by several variables, the most significant of which are the life of the equity award, the exercise price of the security as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock over the term of the equity award.

	The Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development costs, as appropriate, in the Company’s statement of operations.

	The Company issues new shares to satisfy stock option exercises.
Comprehensive Income (Loss)	Comprehensive Income (Loss)

	Components of comprehensive income or loss, including net income or loss, are reported in the financial statements in the period in which they are recognized. Comprehensive income or loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss) are reported net of any related tax effect to arrive at comprehensive income (loss). The Company did not have any items of comprehensive income (loss) for the years ended December 31, 2014 and 2013.
Earnings Per Share	Earnings Per Share

	The Company’s computation of earnings per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income (loss) available to common shareholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., warrants and options) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.

	Loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted loss per common share is the same for all periods presented because all warrants and stock options outstanding are anti-dilutive.

	At December 31, 2014 and 2013, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.

		December 31,
		2014		2013

	Common stock warrants		2,928,800		6,828,800
	Common stock options		6,850,000		3,150,000
	Total		9,778,800		9,978,800
Fair Value of Financial Instruments	Fair Value of Financial Instruments

	The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels, and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required.

	Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives.

	Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges.

	Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models.

	The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end.

	Money market funds are the only financial instrument that is measured and recorded at fair value on the Company’s consolidated balance sheet on a recurring basis.
Use of Estimates	Use of Estimates

	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Recent Accounting Pronouncements	Recent Accounting Pronouncements

	In May 2014, the FASB issued Accounting Standards Update No. 2014-09 (ASU 2014-09), Revenue from Contracts with Customers. ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. ASU 2014-09 also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for reporting periods beginning after December 15, 2016, and early adoption is not permitted. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. As the Company does not expect to have any operating revenues for the foreseeable future, the Company does not expect the adoption of this guidance to have any impact on the Company’s financial statement presentation or disclosures.

	In June 2014, the FASB issued Accounting Standards Update No. 2014-10 (ASU 2014-10), Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. ASU 2014-10 eliminated the requirement to present inception-to-date information about income statement line items, cash flows, and equity transactions, and clarifies how entities should disclose the risks and uncertainties related to their activities. ASU 2014-10 also eliminated an exception provided to development stage entities in Consolidations (ASC Topic 810) for determining whether an entity is a variable interest entity on the basis of the amount of investment equity that is at risk. The presentation and disclosure requirements in Topic 915 will no longer be required for interim and annual reporting periods beginning after December 15, 2014, and the revised consolidation standards will take effect in annual periods beginning after December 15, 2015. Early adoption was permitted. The Company adopted the provisions of ASU 2014-10 effective June 30, 2014, and accordingly, is no longer presenting the inception-to-date financial information and disclosures formerly required in its financial statements.

	In August 2014, the FASB issued Accounting Standards Update No. 2014-15 (ASU 2014-15), Presentation of Financial Statements – Going Concern (Subtopic 205-10). ASU 2014-15 provides guidance as to management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. In connection with preparing financial statements for each annual and interim reporting period, an entity’s management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). Management’s evaluation should be based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued (or at the date that the financial statements are available to be issued when applicable). Substantial doubt about an entity’s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued (or available to be issued). ASU 2014-15 is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company is currently evaluating the impact the adoption of ASU 2014-15 on the Company’s financial statement presentation and disclosures.

	In January 2015, the FASB issued Accounting Standards Update No. 2015-01 (ASU 2015-01), Income Statement – Extraordinary and Unusual Items (Subtopic 225-20). ASU 2015-01 eliminates from GAAP the concept of extraordinary items. Subtopic 225-20, Income Statement—Extraordinary and Unusual Items, required that an entity separately classify, present, and disclose extraordinary events and transactions. Presently, an event or transaction is presumed to be an ordinary and usual activity of the reporting entity unless evidence clearly supports its classification as an extraordinary item. Paragraph 225-20-45-2 contains the following criteria that must both be met for extraordinary classification: (1) Unusual nature. The underlying event or transaction should possess a high degree of abnormality and be of a type clearly unrelated to, or only incidentally related to, the ordinary and typical activities of the entity, taking into account the environment in which the entity operates. (2) Infrequency of occurrence. The underlying event or transaction should be of a type that would not reasonably be expected to recur in the foreseeable future, taking into account the environment in which the entity operates. If an event or transaction meets the criteria for extraordinary classification, an entity is required to segregate the extraordinary item from the results of ordinary operations and show the item separately in the income statement, net of tax, after income from continuing operations. The entity also is required to disclose applicable income taxes and either present or disclose earnings-per-share data applicable to the extraordinary item. ASU 2015-01 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. A reporting entity may apply the guidance prospectively. A reporting entity also may apply the guidance retrospectively to all prior periods presented in the financial statements. Early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption. The adoption of ASU 2015-01 is not expected to have any impact on the Company’s financial statement presentation or disclosures.

	In February 2015, the FASB issued Accounting Standards Update No. 2015-02 (ASU 2015-02), Consolidation (Topic 810). ASU 2015-02 changes the guidance with respect to the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. All legal entities are subject to reevaluation under the revised consolidation mode. ASU 2015-02 affects the following areas: (1) Limited partnerships and similar legal entities. (2) Evaluating fees paid to a decision maker or a service provider as a variable interest. (3) The effect of fee arrangements on the primary beneficiary determination. (4) The effect of related parties on the primary beneficiary determination. (5) Certain investment funds. ASU 2015-02 is effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. If an entity early adopts the guidance in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. A reporting entity may apply the amendments in this guidance using a modified retrospective approach by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption. A reporting entity also may apply the amendments retrospectively. The adoption of ASU 2015-02 is not expected to have any impact on the Company’s financial statement presentation or disclosures.

	Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
Summary of Significant Accounting Policies (Tables)	Dec. 31, 2014
Accounting Policies [Abstract]
Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share	At December 31, 2014 and 2013, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.

		December 31,
		2014		2013

	Common stock warrants		2,928,800		6,828,800
	Common stock options		6,850,000		3,150,000
	Total		9,778,800		9,978,800

Common_Stock_and_Common_Stock_1

Common Stock and Common Stock Warrants (Tables)	12 Months Ended
Common Stock and Common Stock Warrants (Tables)	Dec. 31, 2014
Common Stock And Common Stock Warrants
Schedule of Warrants Outstanding	A summary of common stock warrant activity, including warrants to purchase common stock that were issued in conjunction with the Company’s private placements, is presented below. For presentation purposes, warrants that were extended are considered as outstanding for the entire period in which such extension occurs.

											Weighted
											Average
							Weighted				Remaining
			Number				Average				Contractual
			of				Exercise				Life
			Shares				Price				(in Years)

	Warrants outstanding at December 31, 2012			6,828,800			$	0.667
	Issued			—				—
	Exercised			—				—
	Expired			—				—
	Warrants outstanding at December 31, 2013			6,828,000				0.667
	Issued			—				—
	Exercised			(3,900,000	)			0.263
	Expired			—				—
	Warrants outstanding at December 31, 2014			2,928,800			$	0.592				0.25

	Warrants exercisable at December 31, 2013			6,659,840			$	0.672
	Warrants exercisable at December 31, 2014			2,807,840			$	0.596				0.25
Schedule of Shares Authorized Under Stock Warrants by Exercise Price Range	The exercise prices of common stock warrants outstanding and exercisable are as follows at December 31, 2014:

					Warrants				Warrants
	Exercise				Outstanding				Exercisable
	Prices				(Shares)				(Shares)

	$	0.5				1,853,800				1,732,840
	$	0.75				1,075,000				1,075,000
						2,928,800				2,807,840

Money_Market_Funds_Tables

Money Market Funds (Tables)	12 Months Ended
Money Market Funds (Tables)	Dec. 31, 2014
Investments, Debt and Equity Securities [Abstract]
Fair Value Assets Measured on Recurring Basis	The following table presents money market funds at their level within the fair value hierarchy at December 31, 2014 and 2013.

		Total		Level 1		Level 2		Level 3

	December 31, 2014:
	Money market funds	$	213,699	$	213,699	$	—	$	—

	December 31, 2013:
	Money market funds	$	6,135	$	6,135	$	—	$	—

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	12 Months Ended
Stock-Based Compensation (Tables)	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Fair Value of each Option Award Estimated Assumption	For options granted during the year ended December 31, 2014, the fair value of each option award was estimated using the Black-Scholes option-pricing model with the following assumptions:

	Risk-free interest rate			1.15% to 1.75	%
	Expected dividend yield			0	%
	Expected volatility			173% to 380	%
	Expected life			4-5 years

	For options granted during the year ended December 31, 2013, the fair value of each option award was estimated using the Black-Scholes option-pricing model with the following assumptions:

	Risk-free interest rate			1.51	%
	Expected dividend yield			0	%
	Expected volatility			262	%
	Expected life			5 years
Summary of Stock Option Activity	A summary of stock option activity is presented in the tables below.

											Weighted
											Average
							Weighted				Remaining
			Number				Average				Contractual
			Of				Exercise				Life
			Shares				Price				(in Years)

	Options outstanding at December 31, 2012			3,750,000			$	0.87
	Granted			100,000				0.13
	Exercised			—				—
	Expired			(700,000	)			1.045
	Options outstanding at December 31, 2013			3,150,000				0.818
	Granted			4,700,000				0.473
	Exercised			—				—
	Expired			(1,000,000	)			0.803
	Options outstanding at December 31, 2014			6,850,000			$	0.582				3.57

	Options exercisable at December 31, 2013			3,000,000			$	0.843
	Options exercisable at December 31, 2014			4,675,000			$	0.626				2.84
Exercise Prices of Common Stock Options Outstanding and Exercisable	The exercise prices of common stock options outstanding and exercisable are as follows at December 31, 2014:

					Options				Options
	Exercise				Outstanding				Exercisable
	Prices				(Shares)				(Shares)

	$	0.13				100,000				25,000
	$	0.25				500,000				500,000
	$	0.5				4,300,000				2,200,000
	$	0.65				700,000				700,000
	$	0.98				250,000				250,000
	$	1				1,000,000				1,000,000
						6,850,000				4,675,000

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Components of Deferred Tax Assets	Significant components of the Company’s deferred tax assets as of December 31, 2014 and 2013 are summarized below.

		December 31,
		2014			2013
	Start-up and organization costs	$	49,000		$	56,000
	Research credits		139,000			95,000
	Contingent liability		31,000			31,000
	Stock-based compensation		952,000			750,000
	Net operating loss carryforwards		3,532,000			2,939,000
	Total deferred tax assets		4,703,000			3,871,000
	Valuation allowance		(4,703,000	)		(3,871,000	)
	Net deferred tax assets	$	—		$	—
Schedule of Effective Income Tax Rate	Reconciled below is the difference between the income tax rate computed by applying the U.S. federal statutory rate and the effective tax rate for the years ended December 31, 2014 and 2013.

		Years Ended
		December 31,
		2014			2013

	U. S. federal statutory tax rate		(34.0	)%		(34.0	)%
	Non-deductible stock-based compensation		0.5	%		—	%
	Non-deductible fair value of warrant extensions		3.6	%		—	%
	Non-deductible fair value of warrant discounts		1.6	%		—	%
	Expirations related to stock-based compensation		5	%		13.8	%
	Adjustment to deferred tax asset		(1.0	)%		(1.3	)%
	Change in valuation allowance		24.3	%		21.5	%
	Effective tax rate		0	%		0	%

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
Commitments and Contingencies (Tables)	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Schedule of Principal Cash Obligations and Commitments	The following table sets forth the Company’s principal cash obligations and commitments for the next five fiscal years as of December 31, 2014 aggregating $1,839,548, of which $150,903 is included in current liabilities in the Company’s consolidated balance sheet at December 31, 2014.

				Payments Due By Year
		Total		2015		2016		2017		2018		2019

	Research and development contracts	$	60,530	$	60,530	$	—	$	—	$	—	$	—
	Clinical trial agreements		1,670,301		1,020,301		650,000		—		—		—
	Consulting agreements		16,000		16,000		—		—		—		—
	Due to Chairman and major stockholder		92,717		92,717		—		—		—		—
	Total	$	1,839,548	$	1,189,548	$	650,000	$	—	$	—	$	—

Subsequent_Events_Tables

Subsequent Events (Tables)	12 Months Ended
Subsequent Events (Tables)	Dec. 31, 2014
Subsequent Events [Abstract]
Condensed Consolidated Balance Sheet		Actual - As			Pro Forma - As
		Reported			Adjusted
					(Unaudited)
	ASSETS
	Total current assets	$	539,299		$	2,289,299
	Total assets	$	539,299		$	2,289,299

	LIABILITIES AND STOCKHOLDERS’ EQUITY
	Total current liabilities	$	273,437		$	180,720
	Total liabilities		273,437			180,720

	STOCKHOLDERS’ EQUITY
	Series A convertible preferred stock, $0.0001 par value, $10.00 per share stated value, $50.00 per share redemption value; aggregate dividend equal to 1% of annual net revenue; aggregate redemption value of $8,750,000; liquidation preference based on conversion to common shares; preferred shares authorized: 175,000; preferred shares issued and outstanding: 175,000; common shares issuable upon conversion at 12.5 common shares per share of preferred stock: 2,187,500 shares, as adjusted		—			1,750,000
	Common stock, $0.0001 par value, authorized – 100,000,000 shares; issued and outstanding – 45,483,097 shares, as reported, and 45,575,814 shares, as adjusted		4,548			4,557
	Additional paid-in capital		15,979,475			16,072,183
	Accumulated deficit		(15,718,161	)		(15,718,161	)
	Total stockholders’ equity		265,862			2,108,579
	Total liabilities and stockholders’ equity	$	539,299		$	2,289,299

Organization_and_Business_Oper1

Organization and Business Operations (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Organization And Business Operations [Line Items]
Cost of clinical trial lab	$423,534	$278,721
Cash and money market funds	258,110
June 30, 2015 [Member]
Organization And Business Operations [Line Items]
Estimated cost cf clinical trial lab	2,038,000
June 30, 2016 [Member]
Organization And Business Operations [Line Items]
Estimated cost cf clinical trial lab	2,615,000
March 17, 2015 [Member]
Organization And Business Operations [Line Items]
Proceeds from issuance of preferred stock	$1,750,000

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Patent costs	$342,625	$405,582
Percentage of concentration of risk of general and administrative or research and development costs	10.00%
Deferred setup and organization costs, amortization period	180 months
Unrecognized tax benefits	0	0
Agreement With Theradex Systems [Member]
Clinical cost charged to operations		278,721
Percentage of clinical research and development costs		32.00%
Theradex Systems, Inc [Member]
Clinical cost charged to operations	2,615,000
Percentage of clinical trial service	60.00%
Percentage of clinical center laboratory cost	40.00%
Agreement With Theradex Systems [Member]
Clinical cost charged to operations	$423,534	$278,721
Percentage of clinical research and development costs	38.00%

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Anti-dilutive securities excluded from computation of earnings per share	9,778,800	9,978,800
Stock Options [Member]
Anti-dilutive securities excluded from computation of earnings per share	6,850,000	3,150,000
Common Stock Warrants [Member]
Anti-dilutive securities excluded from computation of earnings per share	2,928,800	6,828,800

Common_Stock_and_Common_Stock_2

Common Stock and Common Stock Warrants (Details Narrative) (USD $)	0 Months Ended			12 Months Ended		1 Months Ended	0 Months Ended
	Jan. 28, 2014	Sep. 08, 2006	Jul. 27, 2006	Dec. 31, 2014	Dec. 31, 2013	Jan. 31, 2014	Jun. 04, 2014	Dec. 31, 2014	Dec. 31, 2014
Percentage of reducing exercise price for currently outstanding warrants	50.00%
Exercise prices of warrants before reduction description	The exercise prices of the warrants before reduction were $0.50 per share (2,253,800 warrants) and $0.75 per share (4,575,000 warrants).
Number of shares issued under discount warrant offer to acquire warrants				3,900,000
Proceeds from exercise of warrants				$1,412,500
Stock options and warrants exercisable fair market value				$0.24	$0.13			$0.24	$0.24
Number of warrants exercisable excluded warrants to acquire				120,960
Percentage of investor prorated liquidated damages equal amount raised per month			1.00%
Number of registered shares sold to private placements		3,555,220
Registration rights penalty obligation				74,000				74,000	74,000
Gain on registration rights penalty obligation		74,000
Minimum [Member]
Warrants exercised at discount price range				$0.25
Maximum [Member]
Warrants exercised at discount price range				$0.38
Warrants One [Member]
Extended outstanding warrants to acquire common stock	1,748,800
Common stock exercisable price per share	0.5
Warrants Two [Member]
Extended outstanding warrants to acquire common stock						815,920
Warrants acquisition expiration date						10-Feb-14
Warrants Three [Member]
Extended outstanding warrants to acquire common stock				312,880
Warrants acquisition expiration date				2-Mar-14
Warrants Four [Member]
Extended outstanding warrants to acquire common stock				620,000
Warrants acquisition expiration date				6-Apr-14
Warrants Extensions One [Member]
Fair value of warrants extensions amount	78,617
Warrants extensions average price per share	0.04
Fair value assumption stock price				$0.15				$0.15	$0.15
Fair value assumptions, exercise price				$0.50				$0.50	$0.50
Fair value assumptions, expected volatility rate				262.00%
Fair value assumptions, expected dividend rate				0.00%
Fair value assumptions, risk free interest rate				1.51%
Warrants Extensions One [Member] \| Minimum [Member]
Fair value assumptions, expected term				13 days
Warrants Extensions One [Member] \| Maximum [Member]
Fair value assumptions, expected term				153 days
Warrants Extensions Two [Member]
Fair value of warrants extensions amount	134,420
Warrants extensions average price per share	0.02
Fair value assumption stock price				$0.15				$0.15	$0.15
Fair value assumptions, expected term				77 days
Fair value assumptions, expected volatility rate				262.00%
Fair value assumptions, expected dividend rate				0.00%
Fair value assumptions, risk free interest rate				1.51%
Warrants Extensions Two [Member] \| Minimum [Member]
Fair value assumptions, exercise price				$0.50				$0.50	$0.50
Warrants Extensions Two [Member] \| Maximum [Member]
Fair value assumptions, exercise price				$0.75				$0.75	$0.75
Warrants Five [Member]
Extended outstanding warrants to acquire common stock							2,928,800
Warrants Six [Member]
Extended outstanding warrants to acquire common stock								1,853,800
Common stock exercisable price per share				$0.50				$0.50	$0.50
Warrants acquisition expiration date								30-Jun-14
Warrant Seven [Member]
Extended outstanding warrants to acquire common stock								1,075,000
Common stock exercisable price per share				$0.75				$0.75	$0.75
Warrants acquisition expiration date								30-Jun-14
Warrants Extensions Three [Member]
Fair value of warrants extensions amount									$224,074
Warrants extensions average price per share				$0.08				$0.08	$0.08
Fair value assumption stock price				$0.22				$0.22	$0.22
Fair value assumptions, expected volatility rate									173.00%
Fair value assumptions, expected dividend rate									0.00%
Fair value assumptions, risk free interest rate									0.10%
Warrants Extensions Three [Member] \| Minimum [Member]
Fair value assumption stock price				$0.50				$0.50	$0.50
Fair value assumptions, expected term				26 days
Warrants Extensions Three [Member] \| Maximum [Member]
Fair value assumption stock price				$0.75				$0.75	$0.75
Fair value assumptions, expected term				300 days

Common_Stock_and_Common_Stock_3

Common Stock and Common Stock Warrants - Schedule of Warrants Outstanding (Details) (Warrant [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Warrant [Member]
Number of Shares, Outstanding, Beginning Balance	6,828,800	6,828,800
Number of Shares, Issued
Number of Shares, Exercised	-3,900,000
Number of Shares, Expired
Number of Shares, Outstanding, Ending Balance	2,928,800	6,828,800
Warrants Exercisable at the end	2,807,840	6,659,840
Weighted Average Exercise Price, Outstanding, Beginning	$0.67	$0.67
Weighted Average Exercise Price, Issued
Weighted Average Exercise Price, Exercised	$0.26
Weighted Average Exercise Price, Expired
Weighted Average Exercise Price, Outstanding, Ending	$0.59	$0.67
Weighted Average Exercise Price, Exercisable at the end	$0.60	$0.67
Weighted Average Remaining Contractual Terms (Years), Outstanding	3 months
Weighted Average Remaining Contractual Terms (Years), Exercisable	3 months

Common_Stock_and_Common_Stock_4

Common Stock and Common Stock Warrants - Schedule of Shares Authorized Under Stock Warrants By Exercise Price Range (Details) (USD $)	Dec. 31, 2014
Warrants Outstanding (Shares)	2,928,800
Warrants Exercisable (Shares)	2,807,840
Exercise Price One [Member]
Exercise Prices	0.5
Warrants Outstanding (Shares)	1,853,800
Warrants Exercisable (Shares)	1,732,840
Exercise Price Two [Member]
Exercise Prices	0.75
Warrants Outstanding (Shares)	1,075,000
Warrants Exercisable (Shares)	1,075,000

Money_Market_Funds_Details_Nar

Money Market Funds (Details Narrative) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Investments, Debt and Equity Securities [Abstract]
Money market funds	$213,699	$6,135

Money_Market_Funds_Fair_Value_

Money Market Funds - Fair Value Assets Measured on Recurring Basis (Details) (Money Market Funds [Member], USD $)	Dec. 31, 2014	Dec. 31, 2013
Assets, fair value disclosure, recurring	$213,699	$6,135
Level 1 [Member]
Assets, fair value disclosure, recurring	213,699	6,135
Level 2 [Member]
Assets, fair value disclosure, recurring
Level 3 [Member]
Assets, fair value disclosure, recurring

Related_Party_Transactions_Det

Related Party Transactions (Details Narrative) (USD $)	12 Months Ended		0 Months Ended
Related Party Transactions (Details Narrative) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Jun. 18, 2014	31-May-12	21-May-12
Due to stockholder	$92,717	$92,717
Legal and consulting fees charged to operations for services rendered by Eric Foreman	46,000	12,000
Fees for services	702,255
Annual cash compensation	25,000
Stock based compensation expense relating to directors officers and other related parties	946,173	119,250
Service cost	25,000
Theradex Systems, Inc [Member]
Clinical cost charged to operations	2,615,000
Percentage of clinical trial service	60.00%
Percentage of clinical center laboratory cost	40.00%
Estimated cost of clinical trial lab	2,615,000
Agreement With Theradex Systems [Member]
Clinical cost charged to operations	423,534	278,721
Consulting Arrangements [Member]
Annual fee payable, clinical trial				25,000
Annual fee payable, clinical trial, installment amount					12,500
Consulting and advisory fees paid		10,417
Dr. Kovach [Member]
Due to stockholder	92,717	92,717
Annual cash compensation	60,000	60,000
Eric Foreman Law Office [Member]
Sub-lease term			6 months
Sub-lease base rate per month			$875

StockBased_Compensation_Detail

Stock-Based Compensation (Details Narrative) (USD $)

0 Months Ended

12 Months Ended

0 Months Ended

Jul. 15, 2014

Dec. 31, 2014

Dec. 31, 2013

Oct. 07, 2014

Jan. 28, 2014

Dec. 24, 2013

Jun. 30, 2011

1-May-11

Sep. 16, 2012

Jun. 26, 2014

Oct. 05, 2011

Oct. 15, 2009

Jun. 20, 2007

Jul. 02, 2011

Options exercisable period

2 years 10 months 2 days

Options, exercisable price per share

$0.63

$0.84

Options, fair value

$43,500

Exercise price per share

$0.04

Stock price per share

$0.15

Fair market value, per share

$0.24

$0.13

Intrinsic value of exercisable but unexercised in-the-money stock options

2,750

Outstanding options to acquire common stock non-vested

2,175,000

Deferred compensation expense for the outstanding value of unvested stock options

69,000

Andrew Robell [Member]

Options granted to purchase common stock

200,000

Options exercisable period

5 years

Options, fair value

20,000

Charges to operations

15,526

Consulting Arrangements [Member]

Charges to operations

434,499

Consulting Arrangements [Member]

Options granted to purchase common stock

4,000,000

Options exercisable period

5 years

Options, exercisable price per share

$0.50

Options vest

2,000,000

Options, fair value

596,400

Charges to operations

298,200

Stock price per share

$0.15

NDA Agreement [Member]

Options exercisable period

5 years

Options, exercisable price per share

$0.13

Options vest

100,000

Options, fair value

12,960

Charges to operations

8,901

Stock price per share

$0.13

Stock Options [Member]

Options, exercisable price per share

Dr. Philip F. Palmedo [Member]

Options granted to purchase common stock

200,000

Options exercisable period

5 years

Options, exercisable price per share

$0.98

Options vest

25,000

Options, fair value

196,000

Charges to operations

48,530

Stock price per share

$0.98

Dr. Ojima [Member]

Options granted to purchase common stock

50,000

Options exercisable period

5 years

Options, exercisable price per share

$0.98

Options vest

6,250

Options, fair value

49,000

Charges to operations

3,357

Stock price per share

$0.98

Dr. Robert B. Royds [Member]

Options granted to purchase common stock

200,000

Options exercisable period

5 years

Options, exercisable price per share

$0.98

Options, fair value

196,000

Charges to operations

8,548

Stock price per share

$0.98

Dr. Robert B. Royds [Member] | Quarterly Vesting Thereafter [Member]

Options vest

25,000

Dr. Kathleen P. Mullinix [Member]

Options exercisable period

5 years

Options, exercisable price per share

$0.65

Options vest

200,000

Options, fair value

118,000

Charges to operations

26,899

58,690

Stock price per share

$0.59

Francis Johnson [Member]

Options exercisable period

5 years

Options, exercisable price per share

$0.25

Options, fair value

$118,650

Stock price per share

$0.24

Daniel Von Hoff [Member]

Options vest

1,000,000

Mr. Schwartzberg [Member]

Options granted to purchase common stock

500,000

Options, exercisable price per share

Option expiration date

5-Oct-16

15-Oct-14

Andrew Robell [Member]

Options, exercisable price per share

$0.50

Options vest

100,000

Stock price per share

$0.10

Andrew Robell [Member] | October 7, 2015 [Member]

Options vest

100,000

2007 Stock Compensation Plan [Member]

Number of restricted stock issued

2,500,000

Options granted to purchase common stock

650,000

Number of option available for issuance

1,850,000

Vesting On January 28, 2015 [Member] | Consulting Arrangements [Member]

Options vest

2,000,000

Options, vesting date

28-Jan-15

Immediate Vesting [Member] | Consulting Arrangements [Member]

Options vest

2,000,000

Immediate Vesting [Member] | NDA Agreement [Member]

Options vest

25,000

Immediate Vesting [Member] | Dr. Robert B. Royds [Member]

Options vest

25,000

Immediate Vesting [Member] | Dr. Kathleen P. Mullinix [Member]

Options vest

25,000

Immediate Vesting [Member] | Francis Johnson [Member]

Options vest

500,000

Quarterly Vesting Thereafter [Member] | Dr. Kathleen P. Mullinix [Member]

Options vest

25,000

Vesting On June 24, 2016 [Member] | NDA Agreement [Member]

Options vest

25,000

Vesting On June 24, 2017 [Member] | NDA Agreement [Member]

Options vest

25,000

StockBased_Compensation_Schedu

Stock-Based Compensation - Schedule of Fair Value of each Option Award Estimated Assumption (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Risk-free interest rate		1.51%
Expected dividend yield	0.00%	0.00%
Expected volatility		262.00%
Expected life		5 years
Minimum [Member]
Risk-free interest rate	1.15%
Expected volatility	173.00%
Expected life	4 years
Maximum [Member]
Risk-free interest rate	1.75%
Expected volatility	380.00%
Expected life	5 years

StockBased_Compensation_Summar

Stock-Based Compensation - Summary of Stock Option Activity (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Beginning Balance - Options outstanding - Number of Shares	3,150,000	3,750,000
Granted - Number of Shares	4,700,000	100,000
Exercised - Number of Shares
Expired - Number of Shares	-1,000,000	-700,000
Ending Balance - Options outstanding - Number of Shares	6,850,000	3,150,000
Options exercisable - Number of Shares at the end	4,675,000	3,000,000
Beginning Balance - Options outstanding - Weighted Average Exercise Price	$0.82	$0.87
Granted - Weighted Average Exercise Price	$0.47	$0.13
Exercised - Weighted Average Exercise Price
Expired - Weighted Average Exercise Price	$0.80	$1.04
Ending Balance - Options outstanding - Weighted Average Exercise Price	$0.58	$0.82
Options exercisable - Weighted Average Exercise Price at the end	$0.63	$0.84
Options outstanding - Weighted Average Remaining Contractual Life (in Years)	3 years 6 months 26 days
Options exercisable - Weighted Average Remaining Contractual Life (in Years)	2 years 10 months 2 days

StockBased_Compensation_Exerci

Stock-Based Compensation - Exercise Prices of Common Stock Options Outstanding and Exercisable (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Exercise Prices	$0.58	$0.82	$0.87
Options Outstanding (Shares)	6,850,000
Options Exercisable (Shares)	4,675,000
Exercise Price Three [Member]
Exercise Prices	$0.50
Options Outstanding (Shares)	4,300,000
Options Exercisable (Shares)	2,200,000
Exercise Price Four [Member]
Exercise Prices	$0.65
Options Outstanding (Shares)	700,000
Options Exercisable (Shares)	700,000
Exercise Price Five [Member]
Exercise Prices	$0.98
Options Outstanding (Shares)	250,000
Options Exercisable (Shares)	250,000
Exercise Price Six [Member]
Exercise Prices	$1
Options Outstanding (Shares)	1,000,000
Options Exercisable (Shares)	1,000,000
Exercise Price One [Member]
Exercise Prices	$0.13
Options Outstanding (Shares)	100,000
Options Exercisable (Shares)	25,000
Exercise Price Two [Member]
Exercise Prices	$0.25
Options Outstanding (Shares)	500,000
Options Exercisable (Shares)	500,000

Income_Taxes_Details_Narrative

Income Taxes (Details Narrative) (USD $)	12 Months Ended
Income Taxes (Details Narrative) (USD $)	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Operating loss carryforwards amount	$8,507,000
Operating loss carryforwards, expiration date	expire through 2033

Income_Taxes_Components_of_Def

Income Taxes - Components of Deferred Tax Assets (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Start-up and organization costs	$49,000	$56,000
Research credits	139,000	95,000
Contingent liability	31,000	31,000
Stock-based compensation	952,000	750,000
Net operating loss carryforwards	3,532,000	2,939,000
Total deferred tax assets	4,703,000	3,871,000
Valuation allowance	-4,703,000	-3,871,000
Net deferred tax assets

Income_Taxes_Schedule_of_Effec

Income Taxes - Schedule of Effective Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
U. S. federal statutory tax rate	-34.00%	-34.00%
Non-deductible stock-based compensation	0.50%	0.00%
Non-deductible fair value of warrant extensions	3.60%	0.00%
Non-deductible fair value of warrant discounts	1.60%	0.00%
Expirations related to stock-based compensation	5.00%	13.80%
Adjustment to deferred tax asset	-1.00%	-1.30%
Change in valuation allowance	24.30%	21.50%
Effective tax rate	0.00%	0.00%

Commitments_and_Contingencies_1

Commitments and Contingencies (Details Narrative) (USD $)	12 Months Ended
Commitments and Contingencies (Details Narrative) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Aggregate principal cash obligation and commitments amount	$1,839,548
Principal cash obligations and commitments, current	150,903
Annual cash compensation	25,000
Operations for services	25,000
Consulting Agreement [Member] \| Dr Von Hoff [Member]
Consulting and advisory fees	4,000
Consulting Arrangements [Member] \| Dr Von Hoff [Member]
Consulting and advisory fees	16,000
Agreement With Theradex Systems [Member]
Clinical cost charged to operations	423,534	278,721
Theradex Systems, Inc [Member]
Clinical cost charged to operations	2,615,000
Percentage of clinical trial service	60.00%
Percentage of clinical center laboratory cost	40.00%
Agreement With Theradex Systems [Member]
Clinical cost charged to operations		$278,721

Commitments_and_Contingencies_2

Commitments and Contingencies - Schedule of Principal Cash Obligations and Commitments (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Research and development contracts	$60,530
Clinical trial agreements	1,670,301
Consulting agreements	16,000
Due to Chairman and major stockholder	92,717	92,717
Total	1,839,548
Payments Due By 2015 [Member]
Research and development contracts	60,530
Clinical trial agreements	1,020,301
Consulting agreements	16,000
Due to Chairman and major stockholder	92,717
Total	1,189,548
Payments Due By 2016 [Member]
Research and development contracts
Clinical trial agreements	650,000
Consulting agreements
Due to Chairman and major stockholder
Total	650,000
Payments Due By 2017 [Member]
Research and development contracts
Clinical trial agreements
Consulting agreements
Due to Chairman and major stockholder
Total
Payments Due By 2018 [Member]
Research and development contracts
Clinical trial agreements
Consulting agreements
Due to Chairman and major stockholder
Total
Payments Due By 2019 [Member]
Research and development contracts
Clinical trial agreements
Consulting agreements
Due to Chairman and major stockholder
Total

Subsequent_Events_Details_Narr

Subsequent Events (Details Narrative) (USD $)	12 Months Ended	0 Months Ended	3 Months Ended	0 Months Ended
Subsequent Events (Details Narrative) (USD $)	Dec. 31, 2014	Mar. 06, 2015	Mar. 31, 2015	Mar. 17, 2015	Dec. 31, 2013	Dec. 31, 2012	Jan. 28, 2014
Warrants outstanding	2,928,800
Common stock weighted average exercise price	$0.58				$0.82	$0.87
Series A Convertible Preferred Stock [Member]
Preferred stock dividend rate percentage	1.00%
Preferred stock terms of conversion	common shares issuable upon conversion at 12.5 common shares per share of preferred stock
Preferred stock converted into common stock	2,187,500
Preferred stock redeem price per share	$50
Warrants One [Member]
Warrants exercisable price per share							$0.50
Subsequent Event [Member]
Proceeds from issuance of warrants			$200,000
Proceeds from issuance of common stock		2,928,800
Common stock weighted average exercise price		$0.30
Subsequent Event [Member] \| Series A Convertible Preferred Stock [Member]
Preferred stock price per shares				$10
Sale of preferred stock shares				175,000
Sale of preferred stock				1,750,000
Subsequent Event [Member] \| Chairman And Major Stockholder [Member]
Issuance of common stock for due to advances				92,717
Issuance of common stock for shares due to advances				92,717
Common stock effective price per share				$1
Common stock closing price per share				$0.25
Subsequent Event [Member] \| Stockholder [Member] \| Securities Purchase Agreement [Member]
Common stock closing price per share				$50
Percentage of issued and outstanding shares of common stock				10.60%
Preferred stock converted into common stock				2,187,500
Subsequent Event [Member] \| Stockholder [Member] \| Securities Purchase Agreement [Member] \| Series A Convertible Preferred Stock [Member]
Common stock effective price per share				$0.80
Common stock closing price per share				$0.25
Purchases of non-voting Series A Convertible Preferred Stock, shares				175,000
Preferred stock price per shares				$10
Purchases of non-voting Series A Convertible Preferred Stock				1,750,000
Preferred stock dividend rate percentage				1.00%
Preferred stock terms of conversion				Each of the Preferred Shares may be converted, at the option of the holder, into 12.5 shares of common stock
Preferred stock converted into common stock				12
Proceeds from issuance of convertible preferred stock				21,875,000
Preferred stock redeem price per share				$50
Subsequent Event [Member] \| Dr. John Kovach [Member]
Issuance of common stock for due to advances				92,717
Issuance of common stock for shares due to advances				92,717
Subsequent Event [Member] \| Warrant [Member]
Percentage of cash reduce of exercise prices of warrants		50.00%
Warrant outstanding to acquire shares of common stock		2,928,800
Warrants outstanding		1,075,000
Warrants exercisable price per share		$0.75
Proceeds from issuance of warrants		$866,575
Subsequent Event [Member] \| Warrants One [Member]
Warrants outstanding		1,853,800
Warrants exercisable price per share		$0.50
Subsequent Event [Member] \| Minimum [Member]
Outstanding common stock purchase warrants extended expiration date		31-Mar-15
Subsequent Event [Member] \| Maximum [Member]
Outstanding common stock purchase warrants extended expiration date		15-Apr-15

Subsequent_Events_Condensed_Co

Subsequent Events - Condensed Consolidated Balance Sheet (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Total current assets	$539,299	$558,040
Total assets	539,299	558,040
Total current liabilities	273,437	321,774
Total liabilities	273,437
Series A convertible preferred stock, $0.0001 par value, $10.00 per share stated value, $50.00 per share redemption value; aggregate dividend equal to 1% of annual net revenue; aggregate redemption value of $8,750,000; liquidation preference based on conversion to common shares; preferred shares authorized: 175,000; preferred shares issued and outstanding: 175,000; common shares issuable upon conversion at 12.5 common shares per share of preferred stock: 2,187,500 shares, as adjusted
Common stock, $0.0001 par value, authorized - 100,000,000 shares; issued and outstanding - 45,483,097 shares, as reported, and 45,575,814 shares, as adjusted	4,548	4,158
Additional paid-in capital	15,979,475	13,184,081
Accumulated deficit	-15,718,161	-12,951,973
Total stockholders' equity	265,862	236,266	1,491,858
Total liabilities and stockholders' equity	539,299	558,040
Series A Convertible Preferred Stock [Member]
Series A convertible preferred stock, $0.0001 par value, $10.00 per share stated value, $50.00 per share redemption value; aggregate dividend equal to 1% of annual net revenue; aggregate redemption value of $8,750,000; liquidation preference based on conversion to common shares; preferred shares authorized: 175,000; preferred shares issued and outstanding: 175,000; common shares issuable upon conversion at 12.5 common shares per share of preferred stock: 2,187,500 shares, as adjusted
Pro Forma - As Adjusted [Member]
Total current assets	2,289,299
Total assets	2,289,299
Total current liabilities	180,720
Total liabilities	180,720
Common stock, $0.0001 par value, authorized - 100,000,000 shares; issued and outstanding - 45,483,097 shares, as reported, and 45,575,814 shares, as adjusted	4,557
Additional paid-in capital	16,072,183
Accumulated deficit	-15,718,161
Total stockholders' equity	2,108,579
Total liabilities and stockholders' equity	2,289,299
Pro Forma - As Adjusted [Member] \| Series A Convertible Preferred Stock [Member]
Series A convertible preferred stock, $0.0001 par value, $10.00 per share stated value, $50.00 per share redemption value; aggregate dividend equal to 1% of annual net revenue; aggregate redemption value of $8,750,000; liquidation preference based on conversion to common shares; preferred shares authorized: 175,000; preferred shares issued and outstanding: 175,000; common shares issuable upon conversion at 12.5 common shares per share of preferred stock: 2,187,500 shares, as adjusted	$1,750,000

Subsequent_Events_Condensed_Co1

Subsequent Events - Condensed Consolidated Balance Sheet (Details) (Parenthetical) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Preferred stock par value	$0.00	$0.00
Preferred stock shares authorized	10,000,000	10,000,000
Preferred stock shares issued	0	0
Preferred stock shares outstanding	0
Common stock par value	$0.00	$0.00
Common stock shares authorized	100,000,000	100,000,000
Common stock shares issued	45,483,097	41,583,097
Common stock shares outstanding	45,483,097	41,583,097
Series A Convertible Preferred Stock [Member]
Preferred stock par value	$0.00
Preferred stock per share stated value	$10
Preferred stock price per redemption value	$50
Preferred stock dividend rate percentage	1.00%
Preferred stock redemption value	$8,750,000
Preferred stock shares authorized	175,000
Preferred stock shares issued	175,000
Preferred stock shares outstanding	175,000
Preferred stock term of conversion	common shares issuable upon conversion at 12.5 common shares per share of preferred stock
Preferred stock converted into common stock	2,187,500
Pro Forma - As Adjusted [Member]
Common stock par value	$0.00
Common stock shares authorized	100,000,000
Common stock shares issued	45,575,814
Common stock shares outstanding	45,575,814
Pro Forma - As Adjusted [Member] \| Series A Convertible Preferred Stock [Member]
Preferred stock par value	$0.00
Preferred stock per share stated value	$10
Preferred stock price per redemption value	$50
Preferred stock dividend rate percentage	1.00%
Preferred stock redemption value	$8,750,000
Preferred stock shares authorized	175,000
Preferred stock shares issued	175,000
Preferred stock shares outstanding	175,000
Preferred stock term of conversion	common shares issuable upon conversion at 12.5 common shares per share of preferred stock
Preferred stock converted into common stock	2,187,500